Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.
Oki Y, Hirose T, Yamaoka T, Kusumoto S, Shirai T, Sugiyama T, Okuda K, Nakashima M, Murata Y, Ohmori T, et al. Cancer Chemother Pharmacol. 2011 Apr; 67(4):791-7. Epub 2010 Jun 17.